Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Taxes (2016 - 2026)

Ani Pharmaceuticals' Current Taxes history spans 12 years, with the latest figure at $1.3 million for Q4 2025.

  • On a quarterly basis, Current Taxes fell 77.04% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 77.04% decrease, with the full-year FY2025 number at $1.3 million, down 77.04% from a year prior.
  • Current Taxes hit $1.3 million in Q4 2025 for Ani Pharmaceuticals, down from $3.3 million in the prior quarter.
  • Over the last five years, Current Taxes for ANIP hit a ceiling of $14.2 million in Q1 2025 and a floor of $594000.0 in Q3 2023.
  • Historically, Current Taxes has averaged $6.0 million across 4 years, with a median of $4.6 million in 2021.
  • The widest YoY moves for Current Taxes: up 24.43% in 2025, down 77.04% in 2025.
  • Tracing ANIP's Current Taxes over 4 years: stood at $3.7 million in 2021, then soared by 123.12% to $8.2 million in 2023, then tumbled by 31.14% to $5.6 million in 2024, then plummeted by 77.04% to $1.3 million in 2025.
  • Business Quant data shows Current Taxes for ANIP at $1.3 million in Q4 2025, $3.3 million in Q2 2025, and $14.2 million in Q1 2025.